07X Stock Chart & Stats
€1.53
€0.02(1.59%)
At close: 4:00 PM EDT
€1.53
€0.02(1.59%)
Day’s Range― - ―
52-Week Range€1.35 - €4.61
Previous CloseN/A
Volume0.00
Average Volume (3M)46.00
Market Cap
€62.77M
Enterprise Value€47.88
Total Cash (Recent Filing)€14.22M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Aug 18, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.72
Shares Outstanding42,541,866
10 Day Avg. Volume42
30 Day Avg. Volume46
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€7.03Price Target Upside359.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.63
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No Reported Debt / Balance-sheet FlexibilityA zero-debt balance sheet reduces default and interest-service risk, giving management flexibility to fund trials via equity or partnerships without fixed liabilities. For a pre-commercial biotech, this structural strength lengthens runway options and lowers bankruptcy risk during multi-year development.
Pivotal Phase 3 Enrollment CompletedCompleting enrollment in a pivotal trial is a durable operational milestone that meaningfully reduces execution risk. It enables planned six-month and 18-month analyses and supports a dual-track regulatory path with potential sequential NDA submissions, strengthening long-term commercialization prospects if data are positive.
Governance Changes And Stronger Equity Incentive FlexibilityExpanded equity compensation capacity and governance approvals support talent retention and alignment of management incentives with shareholders. Stronger governance and auditor ratification improve institutional credibility and help sustain capability to execute complex, multi-year clinical programs.
Bears Say
No Revenue And Persistent Operating LossesZero product revenue and sustained operating losses create ongoing dependence on external financing for core activities. This structural cash deficit elevates dilution and execution risk over the medium term and constrains the company's ability to self-fund development or scale operations without new capital.
Reliance On Dilutive Equity FinancingsRegular recourse to equity offerings is a structural weakness for pre-commercial biotechs: it erodes existing shareholders' ownership and signals persistent cash shortfall. Dependence on dilutive raises can pressure management toward near-term financing milestones rather than long-term value-maximizing choices.
Large, Volatile TTM Loss And Weakened Earnings QualityA sharply larger TTM loss and one-time swings reduce comparability and signal volatile financials. This undermines predictability for planning and increases the probability of additional financing or cost-cutting measures, complicating execution of sustained clinical development programs.
Annovis Bio News
07X FAQ
What was Annovis Bio’s price range in the past 12 months?
Annovis Bio lowest stock price was €1.35 and its highest was €4.61 in the past 12 months.
What is Annovis Bio’s market cap?
Annovis Bio’s market cap is €62.77M.
When is Annovis Bio’s upcoming earnings report date?
Annovis Bio’s upcoming earnings report date is Aug 18, 2026 which is in 19 days.
How were Annovis Bio’s earnings last quarter?
Annovis Bio released its earnings results on May 15, 2026. The company reported -€0.55 earnings per share for the quarter, missing the consensus estimate of -€0.345 by -€0.205.
Is Annovis Bio overvalued?
According to Wall Street analysts Annovis Bio’s price is currently Undervalued.
Does Annovis Bio pay dividends?
Annovis Bio does not currently pay dividends.
What is Annovis Bio’s EPS estimate?
Annovis Bio’s EPS estimate is -0.4.
How many shares outstanding does Annovis Bio have?
Annovis Bio has 42,541,866 shares outstanding.
What happened to Annovis Bio’s price movement after its last earnings report?
Annovis Bio reported an EPS of -€0.55 in its last earnings report, missing expectations of -€0.345. Following the earnings report the stock price went down -4.487%.
Which hedge fund is a major shareholder of Annovis Bio?
Currently, no hedge funds are holding shares in DE:07X
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Annovis Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€7.03 (359.63% Upside)
€7.03 (359.63% Upside)
Blogger Sentiment
Bullish
DE:07X Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $142.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-39.25%
Trailing 12-Months
Company Description
Annovis Bio
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
07X Stock 12 Month Forecast
Average Price Target
€7.03
▲(359.63% Upside)
Technical Analysis
Whitehawk Therapeutics
―
Precision BioSciences
―
Greenwich LifeSciences
―
Acumen Pharmaceuticals
―
Coya Therapeutics, Inc.
―